Selected research
Industry Research
Bio-protein Drug Industry Research Report 2026
Market perspective
The global Bio-protein Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Bio-protein Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Bio-protein Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Bio-protein Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Bio-protein Drug include Abbott Laboratories, Sanofi, Johnson & Johnson, Novartis AG, Merck, Roche, GlaxoSmithKline, Bayer AG and Amgen Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Bio-protein Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Bio-protein Drug Market by Company
Abbott Laboratories
Sanofi
Johnson & Johnson
Novartis AG
Merck
Roche
GlaxoSmithKline
Bayer AG
Amgen Inc.
Reliance Life Science Pvt. Ltd.
ProBioGen AG
Panacea Biotec
Fresenius kabi
Eli Lilly and Company
Dr. Reddy’s Laboratories
Biocon Ltd.
Bio-protein Drug Segment by Type
Therapeutic Proteins
Vaccines
Monoclonal Antibodies
Bio-protein Drug Segment by Application
CROs
Academics
Pharma and Biotech Companies
Bio-protein Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bio-protein Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bio-protein Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bio-protein Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Bio-protein Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Bio-protein Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Bio-protein Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Therapeutic Proteins
- Vaccines
- Monoclonal Antibodies
Applications
- CROs
- Academics
- Pharma and Biotech Companies
Companies covered
- Abbott Laboratories
- Sanofi
- Johnson & Johnson
- Novartis AG
- Merck
- Roche
- GlaxoSmithKline
- Bayer AG
- Amgen Inc.
- Reliance Life Science Pvt. Ltd.
- ProBioGen AG
- Panacea Biotec
- Fresenius kabi
- Eli Lilly and Company
- Dr. Reddy’s Laboratories
- Biocon Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Bio-protein Drug Market Size (2021-2032)
- 2.2.2 Global Bio-protein Drug Sales (2021-2032)
- 2.2.3 Global Bio-protein Drug Market Average Price (2021-2032)
- 2.3 Bio-protein Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Therapeutic Proteins
- 2.3.3 Vaccines
- 2.3.4 Monoclonal Antibodies
- 2.4 Bio-protein Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 CROs
- 2.4.3 Academics
- 2.4.4 Pharma and Biotech Companies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Bio-protein Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Bio-protein Drug Sales (W Tons) of Manufacturers (2021-2026)
- 3.3 Global Bio-protein Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Bio-protein Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Bio-protein Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Bio-protein Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Bio-protein Drug, Product Type & Application
- 3.8 Global Manufacturers of Bio-protein Drug, Established Date
- 3.9 Global Bio-protein Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott Laboratories
- 4.1.1 Abbott Laboratories Company Information
- 4.1.2 Abbott Laboratories Business Overview
- 4.1.3 Abbott Laboratories Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Laboratories Bio-protein Drug Product Portfolio
- 4.1.5 Abbott Laboratories Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Bio-protein Drug Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Johnson & Johnson
- 4.3.1 Johnson & Johnson Company Information
- 4.3.2 Johnson & Johnson Business Overview
- 4.3.3 Johnson & Johnson Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Johnson & Johnson Bio-protein Drug Product Portfolio
- 4.3.5 Johnson & Johnson Recent Developments
- 4.4 Novartis AG
- 4.4.1 Novartis AG Company Information
- 4.4.2 Novartis AG Business Overview
- 4.4.3 Novartis AG Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis AG Bio-protein Drug Product Portfolio
- 4.4.5 Novartis AG Recent Developments
- 4.5 Merck
- 4.5.1 Merck Company Information
- 4.5.2 Merck Business Overview
- 4.5.3 Merck Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Bio-protein Drug Product Portfolio
- 4.5.5 Merck Recent Developments
- 4.6 Roche
- 4.6.1 Roche Company Information
- 4.6.2 Roche Business Overview
- 4.6.3 Roche Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Roche Bio-protein Drug Product Portfolio
- 4.6.5 Roche Recent Developments
- 4.7 GlaxoSmithKline
- 4.7.1 GlaxoSmithKline Company Information
- 4.7.2 GlaxoSmithKline Business Overview
- 4.7.3 GlaxoSmithKline Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GlaxoSmithKline Bio-protein Drug Product Portfolio
- 4.7.5 GlaxoSmithKline Recent Developments
- 4.8 Bayer AG
- 4.8.1 Bayer AG Company Information
- 4.8.2 Bayer AG Business Overview
- 4.8.3 Bayer AG Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bayer AG Bio-protein Drug Product Portfolio
- 4.8.5 Bayer AG Recent Developments
- 4.9 Amgen Inc.
- 4.9.1 Amgen Inc. Company Information
- 4.9.2 Amgen Inc. Business Overview
- 4.9.3 Amgen Inc. Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Amgen Inc. Bio-protein Drug Product Portfolio
- 4.9.5 Amgen Inc. Recent Developments
- 4.10 Reliance Life Science Pvt. Ltd.
- 4.10.1 Reliance Life Science Pvt. Ltd. Company Information
- 4.10.2 Reliance Life Science Pvt. Ltd. Business Overview
- 4.10.3 Reliance Life Science Pvt. Ltd. Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Reliance Life Science Pvt. Ltd. Bio-protein Drug Product Portfolio
- 4.10.5 Reliance Life Science Pvt. Ltd. Recent Developments
- 4.11 ProBioGen AG
- 4.11.1 ProBioGen AG Company Information
- 4.11.2 ProBioGen AG Business Overview
- 4.11.3 ProBioGen AG Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 ProBioGen AG Bio-protein Drug Product Portfolio
- 4.11.5 ProBioGen AG Recent Developments
- 4.12 Panacea Biotec
- 4.12.1 Panacea Biotec Company Information
- 4.12.2 Panacea Biotec Business Overview
- 4.12.3 Panacea Biotec Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Panacea Biotec Bio-protein Drug Product Portfolio
- 4.12.5 Panacea Biotec Recent Developments
- 4.13 Fresenius kabi
- 4.13.1 Fresenius kabi Company Information
- 4.13.2 Fresenius kabi Business Overview
- 4.13.3 Fresenius kabi Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Fresenius kabi Bio-protein Drug Product Portfolio
- 4.13.5 Fresenius kabi Recent Developments
- 4.14 Eli Lilly and Company
- 4.14.1 Eli Lilly and Company Company Information
- 4.14.2 Eli Lilly and Company Business Overview
- 4.14.3 Eli Lilly and Company Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Eli Lilly and Company Bio-protein Drug Product Portfolio
- 4.14.5 Eli Lilly and Company Recent Developments
- 4.15 Dr. Reddy’s Laboratories
- 4.15.1 Dr. Reddy’s Laboratories Company Information
- 4.15.2 Dr. Reddy’s Laboratories Business Overview
- 4.15.3 Dr. Reddy’s Laboratories Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Dr. Reddy’s Laboratories Bio-protein Drug Product Portfolio
- 4.15.5 Dr. Reddy’s Laboratories Recent Developments
- 4.16 Biocon Ltd.
- 4.16.1 Biocon Ltd. Company Information
- 4.16.2 Biocon Ltd. Business Overview
- 4.16.3 Biocon Ltd. Bio-protein Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Biocon Ltd. Bio-protein Drug Product Portfolio
- 4.16.5 Biocon Ltd. Recent Developments
5 Global Bio-protein Drug Market Scenario by Region
- 5.1 Global Bio-protein Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Bio-protein Drug Sales by Region: 2021-2032
- 5.2.1 Global Bio-protein Drug Sales by Region: 2021-2026
- 5.2.2 Global Bio-protein Drug Sales by Region: 2027-2032
- 5.3 Global Bio-protein Drug Revenue by Region: 2021-2032
- 5.3.1 Global Bio-protein Drug Revenue by Region: 2021-2026
- 5.3.2 Global Bio-protein Drug Revenue by Region: 2027-2032
- 5.4 North America Bio-protein Drug Market Facts & Figures by Country
- 5.4.1 North America Bio-protein Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Bio-protein Drug Sales by Country (2021-2032)
- 5.4.3 North America Bio-protein Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Bio-protein Drug Market Facts & Figures by Country
- 5.5.1 Europe Bio-protein Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Bio-protein Drug Sales by Country (2021-2032)
- 5.5.3 Europe Bio-protein Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Bio-protein Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Bio-protein Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Bio-protein Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Bio-protein Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Bio-protein Drug Market Facts & Figures by Country
- 5.7.1 South America Bio-protein Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Bio-protein Drug Sales by Country (2021-2032)
- 5.7.3 South America Bio-protein Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Bio-protein Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Bio-protein Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Bio-protein Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Bio-protein Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Bio-protein Drug Sales by Type (2021-2032)
- 6.1.1 Global Bio-protein Drug Sales by Type (2021-2032) & (W Tons)
- 6.1.2 Global Bio-protein Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Bio-protein Drug Revenue by Type (2021-2032)
- 6.2.1 Global Bio-protein Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Bio-protein Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Bio-protein Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Bio-protein Drug Sales by Application (2021-2032)
- 7.1.1 Global Bio-protein Drug Sales by Application (2021-2032) & (W Tons)
- 7.1.2 Global Bio-protein Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Bio-protein Drug Revenue by Application (2021-2032)
- 7.2.1 Global Bio-protein Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Bio-protein Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Bio-protein Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Bio-protein Drug Value Chain Analysis
- 8.1.1 Bio-protein Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Bio-protein Drug Production Mode & Process
- 8.2 Bio-protein Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Bio-protein Drug Distributors
- 8.2.3 Bio-protein Drug Customers
9 Global Bio-protein Drug Analyzing Market Dynamics
- 9.1 Bio-protein Drug Industry Trends
- 9.2 Bio-protein Drug Industry Drivers
- 9.3 Bio-protein Drug Industry Opportunities and Challenges
- 9.4 Bio-protein Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst